{"schema_version":"secwatch.filing_event.v1","accession":"0001851734-22-000341","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2022-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.580073+00:00","generated_at":"2026-06-24T23:56:06.329417+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"VistaGen terminates President/CSO; PH94B Phase 3 trial completes enrollment","bullets":["President and CSO H. Ralph Snodgrass terminated effective June 15, 2022.","Last patient completed protocol in PALISADE-1 Phase 3 trial of PH94B for social anxiety disorder.","Topline results from PALISADE-1 expected mid-2022; PALISADE-2 topline expected late-2022.","FDA granted Fast Track designation for PH94B in social anxiety disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0001851734-22-000341","json":"https://secwatch.observer/filing/0001851734-22-000341.json","markdown":"https://secwatch.observer/filing/0001851734-22-000341.md","text":"https://secwatch.observer/filing/0001851734-22-000341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/0001851734-22-000341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/vtgn20220622_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:56:06.329417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fbeed7116d","claim":"H. Ralph Snodgrass was terminated as President and Chief Scientific Officer at Vistagen Therapeutics, Inc..","evidence_excerpt":"On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company’s President and Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/0001851734-22-000341-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}